File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Dapsone syndrome in cutaneous lupus erythematosus

TitleDapsone syndrome in cutaneous lupus erythematosus
Authors
Mok, CCLau, CS
KeywordsCutaneous lupus erythematosus
Dapsone
Idiosyncratic reaction
Sulfone
Issue Date1996
PublisherJournal of Rheumatology Publishing Co Ltd. The Journal's web site is located at http://www.jrheum.com
Citation
Journal Of Rheumatology, 1996, v. 23 n. 4, p. 766-768 How to Cite?
AbstractDapsone is increasingly used in the treatment of rheumatic diseases. It is indicated in many inflammatory skin conditions characterized by polymorphonuclear cell infiltration. Minor reactions to the drug are very common, but severe idiosyncratic reactions are rare considering the large number of patients taking this drug worldwide. We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy, with a fatal outcome in one. Physicians should be aware of the potentially lethal side effects of dapsone.
Persistent Identifierhttp://hdl.handle.net/10722/162137
ISSN
0315-162X
2021 Impact Factor: 5.346
2020 SCImago Journal Rankings: 1.577
ISI Accession Number ID
WOS:A1996UE52000037
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorMok, CCen_US
dc.contributor.authorLau, CSen_US
dc.date.accessioned2012-09-05T05:17:34Z-
dc.date.available2012-09-05T05:17:34Z-
dc.date.issued1996en_US
dc.identifier.citationJournal Of Rheumatology, 1996, v. 23 n. 4, p. 766-768en_US
dc.identifier.issn0315-162Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/162137-
dc.description.abstractDapsone is increasingly used in the treatment of rheumatic diseases. It is indicated in many inflammatory skin conditions characterized by polymorphonuclear cell infiltration. Minor reactions to the drug are very common, but severe idiosyncratic reactions are rare considering the large number of patients taking this drug worldwide. We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy, with a fatal outcome in one. Physicians should be aware of the potentially lethal side effects of dapsone.en_US
dc.languageengen_US
dc.publisherJournal of Rheumatology Publishing Co Ltd. The Journal's web site is located at http://www.jrheum.comen_US
dc.relation.ispartofJournal of Rheumatologyen_US
dc.subjectCutaneous lupus erythematosus-
dc.subjectDapsone-
dc.subjectIdiosyncratic reaction-
dc.subjectSulfone-
dc.subject.meshAdulten_US
dc.subject.meshDapsone - Adverse Effectsen_US
dc.subject.meshFatal Outcomeen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLeprostatic Agents - Adverse Effectsen_US
dc.subject.meshLupus Erythematosus, Cutaneous - Drug Therapy - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshSyndromeen_US
dc.titleDapsone syndrome in cutaneous lupus erythematosusen_US
dc.typeArticleen_US
dc.identifier.emailLau, CS:cslau@hku.hken_US
dc.identifier.authorityLau, CS=rp01348en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid8730143en_US
dc.identifier.scopuseid_2-s2.0-0029892123en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0029892123&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume23en_US
dc.identifier.issue4en_US
dc.identifier.spage766en_US
dc.identifier.epage768en_US
dc.identifier.isiWOS:A1996UE52000037-
dc.publisher.placeCanadaen_US
dc.identifier.scopusauthoridMok, CC=34668219600en_US
dc.identifier.scopusauthoridLau, CS=14035682100en_US
dc.identifier.issnl0315-162X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats